Increasing Prevalence of cardiovascular diseases have stimulated the Cardiac Valve Global Market By 2032 ; Asserts MRFR Unleashing Industry Forecast

Pune, India, 2023 /MRFR Press Release/- Market Research Future published a Half-Cooked Research Report on “Global Cardiac Valve Market Research Report - Forecast to 2032”  – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2032.

Global Cardiac Valve Market - Overview

Cardiac valve or heart valve allows blood to flow in only one direction through the heart. Human heart consists of four valves. These valves open and closes compulsory on differential blood pressure on each side. Main role is when blood enters the heart first passes through the tricuspid valve and then the pulmonary valve. After returning from the lungs, the blood passes through the mitral valve and exits via the aortic valve as heart valves are one-way valves. 

Furthermore, valve replacement remains the most widely used technique but the proportion of valve repair procedures is increasing in experienced treatment centres. Moreover, increasing development in medical technology and its wide range of application used in the treatment of various cardiac diseases will fuel the growth of the market. However, high cost of the treatment likely to restrain the growth of the market over the assessment period.

The Cardiac Valve Market Size will rake USD 12.7 Billion in revenues while expanding with an 6.50 % CAGR in the 2023-2032.

Global Cardiac Valve Market   - Competitive Analysis

June, 2017- Edwards Life sciences Corporation SAPIEN 3 Valve received FDA approval for Aortic, Mitral Valve-In-Valve Procedures. Expansion of the SAPIEN 3 device indication to include valve-in-valve procedures is a meaningful advancement for patients at high risk of an additional open-heart valve procedure, particularly for those in need of a safe alternative for mitral valve replacement. According to Edwards Life sciences Corporation company report this approval brings a safe and effective transcatheter therapy to patients who would do very poorly with repeat open-heart surgery

March, 2017- Boston Scientific is acquired Swiss company Symetis, move made by the medical device giant to strengthen its portfolio of minimally invasive heart valve replacement products. Symetis makes heart products for transcatheter aortic valve replacement, a minimally invasive procedure that uses a catheter to deploy a valve that takes over for an old, damaged one. Moreover, company has commercialized two heart valve systems i.e the Acurate TA and the Acurate neo/TF valve. Both are sold in Europe and some other markets, but not the U.S. The company also has an investigational next generation valve system that is currently in clinical testing. 

Dec, 2016- Boston Scientific acquired Neovasc advanced biological tissue capabilities. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace, including the Tiara technology in development for the transcatheter treatment of mitral valve disease, and the Neovasc Reducer technology for the treatment of refractory angina. Neovasc advanced biological tissue capabilities had integrated into the Boston Scientific structural heart business for use in the manufacturing of the Lotus valve and future heart valve technologies.

August, 2015- Medtronic to acquired Twelve, Inc., developer of transcatheter mitral valve replacement device. Twelve, Inc., a privately held medical device company based in Redwood City, California, focuses on the development of a transcatheter mitral valve replacement (TMVR) device. This acquisition had strategically augmented existing capabilities in the transcatheter mitral space, which represents an important growth opportunity for Medtronic. Twelve's technology is a truly creative solution that brings together valve technology with a unique and highly differentiated dual-stent fixation design.
Medtronic (U.S.), Edwards Lifesciences Corporation (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.), LivaNova PLC (U.K), Symetis SA (Switzerland), Jenavalve Technology, Inc. (Germany), CryoLife, Inc. (U.S.), TTK HealthCare (India), Colibri Heart Valve, LLC (U.S.), Lepu Medical Technology Co., Ltd. (China), and Braile Biomédica (Brazil) are some of the prominent players at the forefront of competition in the Global Cardiac Valve Market and are profiled in MRFR Analysis. 

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Cardiac Valve Market Research Report

 Global Cardiac Valve Market - Regional Analysis

The Americas dominates the global cardiac valve market. North America is the largest market owing to rising prevalence of cardiovascular patient population in the American counties and well-developed technology in this region. According to the Centres for Disease Control and Prevention, heart disease causes 35% of deaths in the United States. About 610,000 people died of heart disease in the United States every year that makes up 1 in every 4 deaths. Heart disease is the leading cause of death for both men and women. According to Texas heart Institute, in the United States, surgeons perform about 106,000 heart valve operations each year and all of these operations are done to repair or replace the mitral or aortic valves.